Dr. Mehta has published over 230 articles and holds peer-review operating grants from the CIHR, Heart and Stroke Foundation of Canada and industry. He has led large-scale trials evaluating antiplatelet therapy in patients with acute coronary syndromes, having been the Principal Investigator of the PCI-CURE study establishing the benefit of clopidogrel in patients with ACS undergoing PCI and the 25,000 patient CURRENT-OASIS 7 trial evaluating aspirin and clopidogrel dosing. He is the Principal Investigator of PREMISE, a Canadian multicenter registry of patients undergoing percutaneous mitral valve repair with the Mitraclip. He has also led landmark trials evaluating pragmatic interventions in ACS, including RIVAL, establishing the benefit of a radial artery versus femoral artery approach in patients with ACS, TIMACS evaluating optimal timing of invasive intervention in patients with ACS and the recently published COMPELTE trial evaluating a strategy of complete revascularization in patients with STEMI and multivessel disease. The COMPLETE trial was recognized by the editors of the New England Journal of Medicine as one of its Most Notable Articles of 2019.